Predictors of the Use of Specific Critical Care Therapies in Patients With Metastatic Cancer
Author Department
Healthcare Quality; Medicine
Document Type
Article, Peer-reviewed
Publication Date
1-2017
Abstract
OBJECTIVE:
Understanding which factors are associated with the use of critical care therapies (CCTs) can help with clinical decision-making and goals of care discussion. The goal of this study was to describe the predictors of CCT use (eg, mechanical ventilation, tracheostomy, percutaneous endoscopic gastrostomy tube, total parenteral nutrition, acute use of dialysis) in hospitalized patients with metastatic cancer.
METHODS:
We used the 2010 California State Inpatient Databases sponsored by the Agency for Healthcare Research and Quality to identify all hospitalizations with a diagnosis of metastatic cancer (patients aged ≥18 years). We examined the predictors of any CCT use (and invasive mechanical ventilation [IMV] use), stratified by do-not-resuscitate (DNR) status, using multivariable logistic regression models.
RESULTS:
We identified 99,085 hospitalizations involving patients with metastatic cancer; 9.4% received any CCTs and 4.7% received IMV. Predictors of CCT use in the no-DNR group included principal diagnosis of infections (vs cancer-related), greater burden of comorbidities, and presence of weight loss. Predictors of CCT use in the DNR group were similar, but also included non-white races. Liver disease was also a predictor of IMV use in the no-DNR group. Patients with metastatic lung cancer (vs breast and genitourinary) with no DNR were more likely to receive CCT (and IMV).
CONCLUSIONS:
Higher burden of comorbidities, weight loss, liver disease, lung cancer subtype, and diagnosis of infections were associated with higher odds of receiving CCTs or IMV. These findings may help clinicians determine in whom to prioritize discussions around goals of care, especially in the group without a DNR status.
Recommended Citation
Loh KP, Kansagra A, Shieh MS, Pekow P, Lindenauer P, Stefan M, Lagu T. Predictors of the Use of Specific Critical Care Therapies in Patients With Metastatic Cancer. J Natl Compr Canc Netw. 2017 Jan;15(1):22-30.
PMID
28040717